Dataset from A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00010129
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the efficacy and safety of ibrutinib versus
rituximab in adult Asia Pacific region patients with relapsed or refractory chronic
lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
创建时间：
2025-02-10
